Endothelial cells do not arise from tumor-initiating cells in human hepatocellular carcinoma

BMC Cancer

Anand Ghanekar³  Sharif Ahmed²  Kui Chen²  Oyedele Adeyi¹ 

[1] Department of Pathology, University Health Network, Toronto, ON, Canada

[2] Toronto General Research Institute, University Health Network, Toronto, ON, Canada

[3] Toronto General Hospital, University Health Network, NCSB 11C-1227, 585 University Avenue, Toronto, ON M5G 2N2, Canada

关键词: Recurrence;    Liver transplantation;    Xenograft;    CD34;    CD31;    Tumor-initiating cell;    Cancer stem cell;    Angiogenesis;    Endothelial cell;    Hepatocellular carcinoma;   

Others  :  1079508
DOI  :  10.1186/1471-2407-13-485

 received in 2013-07-26, accepted in 2013-10-15,  发布年份 2013

【 摘 要 】

Background

Conventional models of carcinogenesis suggest that tumors recruit blood vessel formation from normal host tissues. This concept has recently been challenged by prominent studies of glioblastoma, which suggest that intratumoral endothelial cells (ECs) may arise from cancer stem cells/tumor-initiating cells (TICs). Hepatocellular carcinoma (HCC) is a common, highly vascularized tumor with few effective therapies, against which anti-angiogenic strategies are being actively explored. TICs are felt to play a role in HCC pathobiology, but their contributions to tumor vasculature have not been studied.

Methods

We examined human HCCs in settings that selected for tumor formation from functionally defined TICs, and in which the origin of intratumoral ECs from TICs as opposed to host tissues could be clearly distinguished. We generated HCC nodules in the livers of immunodeficient mice by intrasplenic injection of HCC cells from cell lines and patient specimens and studied the tumor ECs by immunohistochemistry for mouse and human markers. We then used immunohistochemistry for EC markers in combination with fluorescence in situ hybridization (FISH) for X and Y chromosomes to study the endothelium of recurrent HCC specimens resected from sex-mismatched liver allografts of patients who had undergone liver transplantation for HCC.

Results

We observed that all ECs in intrahepatic human HCC xenografts expressed mouse rather than human CD31. FISH analysis of recurrent HCCs resected from patients with sex-mismatched liver allografts revealed that all CD31⁺ and CD34⁺ intratumoral ECs originated from the donor allograft rather than the tumor.

Conclusions

These observations suggest that the vasculature of human HCC arises from normal host tissues rather than from TICs, supporting ongoing efforts to target angiogenesis in HCC as it is currently understood, and suggesting that the contribution of TICs to the vasculature of other cancers is disease-specific.

【 授权许可】

   
2013 Ghanekar et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
• [2]Ping YF, Bian XW: Concise review: contribution of cancer stem cells to neovascularization. Stem Cells 2011, 29(6):888-894.
• [3]Ricci-Vitiani L, Pallini R, Biffoni M, Todaro M, Invernici G, Cenci T, Maira G, Parati EA, Stassi G, Larocca LM, et al.: Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468(7325):824-828.
• [4]Wang R, Chadalavada K, Wilshire J, Kowalik U, Hovinga KE, Geber A, Fligelman B, Leversha M, Brennan C, Tabar V: Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468(7325):829-833.
• [5]El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132(7):2557-2576.
• [6]Bruix J, Sherman M: Management of hepatocellular carcinoma. Hepatology 2005, 42(5):1208-1236.
• [7]Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359(4):378-390.
• [8]Tang A, Cruite I, Sirlin CB: Toward a standardized system for hepatocellular carcinoma diagnosis using computed tomography and MRI. Expert Rev Gastroenterol Hepatol 2013, 7(3):269-279.
• [9]Pang R, Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett 2006, 242(2):151-167.
• [10]Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007, 132(7):2542-2556.
• [11]Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, Ye Q, Qin LX, Wauthier E, et al.: EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136(3):1012-1024.
• [12]Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, Chu PW, Lam CT, Poon RT, Fan ST: Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 2008, 13(2):153-166.
• [13]Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO: CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell 2011, 9(1):50-63.
• [14]Chen K, Ahmed S, Adeyi O, Dick JE, Ghanekar A: Human solid tumor xenografts in immunodeficient mice are vulnerable to lymphomagenesis associated with Epstein-Barr virus. PLoS One 2012, 7(6):e39294.
• [15]Lafreniere R, Rosenberg SA: A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 1986, 76(2):309-322.
• [16]Ahmed S, Zair M, Chen K, Iu M, He F, Adeyi O, Cleary S, Ghanekar A: Generation of subcutaneous and intrahepatic human hepatocellular carcinoma xenografts in immunodeficient mice. J Vis Exp 2013, 79:e50544.
• [17]DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, Cattral MS, McGilvray I, Ghanekar A, Selzner M, Greig PD, et al.: Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011, 253(1):166-172.
• [18]Cui S, Hano H, Sakata A, Harada T, Liu T, Takai S, Ushigome S: Enhanced CD34 expression of sinusoid-like vascular endothelial cells in hepatocellular carcinoma. Pathol Int 1996, 46(10):751-756.
• [19]Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A: Tumor growth need not be driven by rare cancer stem cells. Science 2007, 317(5836):337.
• [20]Penn I: Post-transplant malignancy: the role of immunosuppression. Drug Saf 2000, 23(2):101-113.
• [21]Albini A, Tosetti F, Li VW, Noonan DM, Li WW: Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012, 9(9):498-509.